Human monoclonal ScFv that inhibits cellular entry and metalloprotease activity of tetanus neurotoxin

Asian Pacific Journal of Allergy and Immunology

Volumn 28, Issue 1, 2010, Pages 85-93

  Indrawattana, Nitaya ^a   Sookrung, Nitat ^b   Kulkeaw, Kasem ^b   Seesuay, Watee ^b   Kongngoen, Thida ^a   Chongsa nguan, Manas ^a   Tungtrongchitr, Anchalee ^b   Chaicumpa, Wanpen ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; METALLOPROTEINASE; NEUROTOXIN; RECOMBINANT PROTEIN; RETINOIC ACID; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SYNAPTOBREVIN; TETANUS TOXIN; TETANUS TOXOID; UNCLASSIFIED DRUG; ZINC METALLOPROTEINASE;

ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BIOPANNING; CELL PERMEABILIZATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; MOLECULAR CLONING; NEUROBLASTOMA CELL; NONHUMAN; PHAGE DISPLAY; PHAGEMID; PROTEIN CLEAVAGE;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CLOSTRIDIUM TETANI; HUMANS; IMMUNIZATION, PASSIVE; METALLOENDOPEPTIDASES; METALLOPROTEASES; NEURONS; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN ENGINEERING; R-SNARE PROTEINS; RECEPTORS, CELL SURFACE; SINGLE-CHAIN ANTIBODIES; TETANUS; TETANUS TOXIN;

EID: 77954561384     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Goonetilleke A, Harris JB. Clostridial neurotoxins. J Neurol Neurosurg Phsychiatry 2004; 75: iii35-9.
2. Rao KN, Kumaran D, Binz T, Swanminathan S. Structural analysis of the catalytic domain of tetanus neurotoxin. Toxicon 2005; 45: 929-39.
3. Halpern JL, Neale EA. Neurospecific binding, internalization, and retrograde axonal transport. Curr Top Microbiol Immunol 1995; 195: 221-41.
4. Shapiro ER, Specht DC, Collins EB, et al. Identification of a ganglioside recognition domain of tetanus toxin using a novel ganglioside photoaffinity ligand. J Biol Chem 1997; 272: 30380-6.
5. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359: 832-5.
6. Sikorra S, Henke T, Galli T, Binz T. Substrate recognition mechanism of VAMP/synaptobrevincleaving clostridial neurotoxins. J Biol Chem 2008; 283: 21145-52.
7. Helting BT, Zwisler O. Structure of tetanus toxin: I. Break-down of the molecule and discrimination between polypeptide fragments. J Biol Chem 1977; 252: 187-193.
8. Bernard B. Tetanus toxin. Microbiol Rev 1979; 43: 224-40.
9. Clara SL, William HH, Carolyn HM. Antibodies against the light chain of tetanus toxin in human sera. Infect Immun 1985; 49: 111-5.
10. Wassilak SGF, Orenstein WA, Sutter RW. Tetanus Toxoid. In: Vaccines, 5th edition, Plotkin SA, Orenstein WA, eds. Philadelphia, PA, WB Saunders, 2008, pp. 805-39.
11. Stanfield JP, Galazka A. Neonatal tetanus in the world today. Bull WHO 1984; 62: 647-69.
12. Goulon M, Girard O, Grosbuis S, Desormeau JP, Capponi MF. Changes in antitetanus antibodies under serotoxoid therapy. Study in 50 patients with tetanus. Nouv Presse Med 1976; 5: 847-50.
13. Gibson RB, Banzhaf EJ. The quantitative changes in the protein in the blood plasma of horse in the course of immunization. J Exp Med 1910; 12: 411-34.
14. Kulkeaw K, Sakolvaree Y, Srimanote P, et al. Human monoclonal ScFv neutralize lethal Thai cobra, Naja kaouthia, neurotoxin. J Proteomics 2009; 72: 270-82.
15. Poungpair O, Chaicumpa W, Kulkeaw K, et al. Human single chain monoclonal antibody that recognizes matrix protein of heterologous influenza A virus subtypes. J Virol Methods 2009; 159: 105-11.
16. Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of proteindye-binding. Anal Biochem 1976; 72: 248-54.
17. Laemmili UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
18. Thathaisong U, Maneewatch S, Kulkeaw K, et al. Human monoclonal single chain antibodies (huScFv) that bind to the polymerase proteins of influenza A virus. Asian Pac J Allergy Immunol. 2008; 26: 23-35.
19. Hill PD, Robertson AK. Characterization of the cholinergic differentiation of the human neuroblastoma cell line LA-N-5 after treatment with retinoic acid. Dev Brain Res 1997; 102: 53-67.
20. Sanford PJ. Tetanus-forgotten but not gone. N Engl J Med 1995; 332: 812-3.
21. Matsuda M, Makinaga G, Hirai T. Studies on the antibody composition and neutralizing activity of tetanus antitoxin sera from various species of animals in relation to the antigenic substructure of the tetanus toxin molecule. Biken J 1983; 26: 133-43.
22. Kistner A, Habermann E. Reductive cleavage of tetanus toxin and botulinum neurotoxin A by the thioredoxin system from brain. Naunyn Schmiedebergs Arch Pharmacol 1992; 345: 227-34.
23. Koch-Nolte F, Reyelt J, Schössow B, et al. Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo. FASEB 2007; 21: 3490-8.
24. Maneewatch S, Thanongsaksrikul J, Songserm T, et al. Human single-chain antibodies that neutralize homologous and heterologous strains and clades of influenza A virus subtype H5N1. Antivir Ther 2009; 14: 221-30.
25. Thanongsaksrikul J, Srimanote P, Maneewatch S, et al. A VHH that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type A. J Biol Chem 2010; 285: 9657-66.